Icotrokinra: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข2 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions for icotrokinra tablets have not been publicly disclosed in detail. Standard pharmaceutical oral tablet storage (room temperature, protected from moisture and light) is expected based on clinical trial protocols.
Protocol Quick-Reference
Moderate-to-severe plaque psoriasis
Dosing
Amount
200 mg
Frequency
Once daily
Duration
Ongoing
Step-wise Titration
Administration
Route
OralSchedule
N/A (oral tablet)
Timing
Once-daily oral tablet; no specific timing relative to meals reported
Cycle
Duration
Ongoing (continuous treatment)
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Store at room temperature; protect from moisture and light
โ๏ธ Suggested Bloodwork (3 tests)
When:
Why:
When:
Why:
When:
Why:
๐ก Key Considerations
- โInvestigational drug - not yet approved by any regulatory authority
- โNDA submitted to FDA July 2025
- โNo dose adjustment required based on body weight in clinical trials
- โOral administration eliminates need for injection training
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Moderate-to-Severe Plaque Psoriasis (Phase 3 Dose) | 200 mg orally once daily | Once daily oral administration | Ongoing (continuous treatment for sustained efficacy) | This dose was used in all four Phase 3 ICONIC trials. Selected based on pharmacokinetic modeling from Phase 2b FRONTIER 1 data. Taken as a single daily tablet. |
| Moderate-to-Severe Plaque Psoriasis (Phase 2b Highest Dose) | 100 mg orally twice daily | Twice daily oral administration | 16 weeks evaluated in FRONTIER 1 | Highest dose tested in Phase 2b, achieving 79% PASI 75 response. The Phase 3 dose of 200 mg QD was modeled to provide comparable daily exposure with improved convenience. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
No reconstitution required. Icotrokinra is formulated as an oral tablet for direct administration. This is a key advantage over injectable peptides that require reconstitution.
๐งStorage Requirements
Storage conditions for icotrokinra tablets have not been publicly disclosed in detail. Standard pharmaceutical oral tablet storage (room temperature, protected from moisture and light) is expected based on clinical trial protocols.
Community Dosing Protocols
Compare these clinical doses with what 25+ community members report using.
Based on 25+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Status#
Icotrokinra (JNJ-2113) is an investigational medication that has not yet received regulatory approval. An NDA was submitted to the FDA in July 2025 for moderate-to-severe plaque psoriasis. All dosing information is derived from published clinical trial data. Dosing should only occur within the context of clinical trials or, once approved, under the guidance of a qualified dermatologist.
Clinical Trial Dosing#
Phase 3 ICONIC Program (200 mg QD)#
All four Phase 3 ICONIC trials used the same dosing regimen:
- Dose: 200 mg orally once daily
- Formulation: Oral tablet
- Duration: Continuous treatment (placebo crossover at week 16)
- Weight-based adjustment: Not required
- Timing: No specific meal timing requirements reported
This fixed dose was selected based on pharmacokinetic modeling from the Phase 2b FRONTIER 1 data, designed to provide daily exposure comparable to the 100 mg BID regimen that achieved the highest efficacy in Phase 2b.
Phase 2b FRONTIER 1 (Dose-Ranging)#
The FRONTIER 1 trial evaluated five dosing regimens over 16 weeks:
| Regimen | PASI 75 at Week 16 | IGA 0 at Week 16 |
|---|---|---|
| 25 mg QD | 37% | 10% |
| 25 mg BID | 58% | 26% |
| 50 mg QD | 56% | 17% |
| 100 mg QD | 73% | 37% |
| 100 mg BID | 79% | 45% |
| Placebo | 9% | 0% |
The clear dose-response relationship informed the selection of 200 mg QD for Phase 3, balancing efficacy with the convenience of once-daily dosing.
Administration#
Oral Tablet Administration#
- Take one 200 mg tablet by mouth once daily
- Swallow whole (no crushing, splitting, or chewing data available)
- No reported food effect requirements
- Take at approximately the same time each day for consistency
Advantages Over Injectable Biologics#
Icotrokinra's oral formulation eliminates several practical considerations associated with injectable psoriasis therapies:
- No injection site rotation needed
- No reconstitution or cold-chain storage requirements
- No injection site reactions
- No need for healthcare provider administration or self-injection training
Monitoring Recommendations (Based on Clinical Trial Protocols)#
- Baseline: Complete blood count, liver function, infection screening (including TB)
- Periodic: CBC with differential, liver function tests
- Clinical assessment: PASI, IGA, and body surface area at scheduled intervals
Treatment Considerations#
Onset and Duration of Response#
- Meaningful separation from placebo was observed by week 4 in Phase 2b
- Co-primary endpoints assessed at week 16
- Continued improvement observed from week 16 to week 24
- Long-term maintenance of response demonstrated through week 52 in ICONIC-TOTAL
Treatment Interruption#
The reversibility of IL-23R blockade suggests that disease activity would be expected to return upon discontinuation, consistent with the pharmacology of injectable IL-23 inhibitors. Formal treatment interruption and retreatment data have not been published.
Dosing Context#
Icotrokinra belongs to the Skin category of research peptides, with secondary relevance to the Immune category. Dosing protocols are derived from published clinical trial data in the NEJM (2024, 2025) and Lancet (2025). These protocols are provided for research reference only and do not constitute medical advice.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Icotrokinra
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.